CompletedNCT04807517
Buspirone for anxiety in people with Williams syndrome
About this title
Read the official source — NCT04807517Medication studyAges 5–65United States
Understand this study
Who was this study for?
This study was for people with anxiety. Listed age limits: 5 years to 65 years. Other eligibility criteria applied.
- Listed locations
- LexingtonSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: August 1, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 20
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 5 Years to 65 Years
- Official registry ID
- NCT04807517
- Official title
Show the full official title
Buspirone for the Treatment of Anxiety in Williams Syndrome
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Lexington
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Buspirone.
Who was this study for?
This study was for people with anxiety. Listed age limits: 5 years to 65 years. Other eligibility criteria applied.
